SVRA: Done with phase 3, ready for approvalSavara, Inc.BATS:SVRAHappy_CandlesSVRA As of early 2026, Savara is in a strong position for a biotech: They have approximately $196 million in cash, which they believe is sufficient to fund operations into Q2 2027. This reduces the risk of a "surprise" dilution/offering before the FDA decision. Wall Street is highly bullish. Firms like Jefferies and H.C. Wainwright have price targets ranging from $10.00 to $10.50, representing nearly 100% upside from current levels. The bottom line, If you are looking at a classic "Buy the Rumor" setup. The stock has run up on Phase 3 success and is now resting (the Flag) while investors wait for the FDA decision in August. If the flag breaks to the upside, it often moves a distance equal to the length of the "pole"—which would put the target well into the double digits. A break above the top of the flag with volume is my entry trigger.